



NewLink Genetics Corporation
Investor Relations Department
2503 South Loop Drive
Ames, IA 50010
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

Company Profile

Founded in 1999, NewLink Genetics is an immuno-oncology company focused on discovering and developing novel products for the treatment of cancer. The drug discovery and development teams at NewLink Genetics are relentlessly pursuing a wide range of immuno-oncology portfolio candidates with the potential to change the oncology landscape. NewLink Genetics' portfolio includes two small-molecule product candidates currently in clinical development. These product candidates inhibit the IDO pathway, a key immuno-oncology target, and focus on breaking the immune system's tolerance to cancer.

Press Releases [\[View all \]](#)

Jun 8, 2017

[NewLink Genetics to Regain Rights to GDC-0919](#)

Jun 5, 2017

[NewLink Genetics' Indoximod + PROVENGE® Results in Statistically Significant Improvement in Radiographic Progression-Free Survival \(rPFS\) for Patients with Metastatic Castration Resistant Prostate Cancer \(mCRPC\) in Phase 2 Trial](#)

Jun 2, 2017

[Results from Clinical Trial of Indoximod Plus Chemotherapy for Patients with Metastatic Breast Cancer](#)

May 18, 2017

[Data from Clinical Study of NewLink Genetics' IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association Congress](#)

May 17, 2017

[Data from Clinical Studies of NewLink Genetics' Two Distinct IDO Pathway Inhibitors to Be Presented at ASCO 2017](#)

Financials [\[View all \]](#)

[First Quarter Financial Results](#)

Mar 6, 2017

[Annual Report \(10-K\)](#)

Mar 31, 2017

[Proxy Statement \(DEF 14A\)](#)

May 5, 2017

[Quarterly Report \(10-Q\)](#)

Nov 8, 2016

[Quarterly Report \(10-Q\)](#)

Aug 5, 2016

[Quarterly Report \(10-Q\)](#)